These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16960474)

  • 1. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.
    Hellwig K; Schimrigk S; Lukas C; Hoffmann V; Brune N; Przuntek H; Müller T
    Clin Neuropharmacol; 2006; 29(5):286-91. PubMed ID: 16960474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms.
    Hellwig K; Stein FJ; Przuntek H; Müller T
    BMC Neurol; 2004 Nov; 4(1):18. PubMed ID: 15530171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in the free radical status and clinical benefit of repeated intrathecal triamcinolone acetonide application in patients with progressive multiple sclerosis.
    Müller T; Herrling T; Lütge S; Küchler M; Lohse L; Rothe H; Haas T; Marg M; Öhm G; Jung K
    Clin Neuropharmacol; 2014; 37(1):22-5. PubMed ID: 24434528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.
    Hoffmann V; Schimrigk S; Islamova S; Hellwig K; Lukas C; Brune N; Pöhlau D; Przuntek H; Müller T
    J Neurol Sci; 2003 Jul; 211(1-2):81-4. PubMed ID: 12767502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.
    Ehrenreich H; Fischer B; Norra C; Schellenberger F; Stender N; Stiefel M; Sirén AL; Paulus W; Nave KA; Gold R; Bartels C
    Brain; 2007 Oct; 130(Pt 10):2577-88. PubMed ID: 17728357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
    Singhal BS; Geeta S; Hundalani SG; Menon S
    Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients.
    Hoffmann V; Kuhn W; Schimrigk S; Islamova S; Hellwig K; Lukas C; Brune N; Pöhlau D; Przuntek H; Müller T
    Eur J Neurol; 2006 Jan; 13(1):72-6. PubMed ID: 16420395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
    Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
    Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of intraspinal steroid application in patients with multiple sclerosis.
    Müller T
    Expert Rev Neurother; 2009 Sep; 9(9):1279-87. PubMed ID: 19769444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of pimecrolimus cream versus triamcinolone acetonide paste in the treatment of oral lichen planus.
    Gorouhi F; Solhpour A; Beitollahi JM; Afshar S; Davari P; Hashemi P; Nassiri Kashani M; Firooz A
    J Am Acad Dermatol; 2007 Nov; 57(5):806-13. PubMed ID: 17658663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration.
    Abu-Mugheisib M; Benecke R; Zettl UK
    Curr Pharm Des; 2012; 18(29):4564-9. PubMed ID: 22612755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.
    Müller T; Barghorn S; Lütge S; Haas T; Mueller R; Gerlach B; Öhm G; Eilert K; Trommer I; Mueller BK
    J Neural Transm (Vienna); 2015 Jun; 122(6):841-8. PubMed ID: 25209051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective use of intramuscular triamcinolone acetonide in pseudogout.
    Roane DW; Harris MD; Carpenter MT; Finger DR; Jarek MJ; Alloway JA; Erickson AR; Venanzi WE; Drehmer TJ
    J Rheumatol; 1997 Jun; 24(6):1168-70. PubMed ID: 9195527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
    Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
    Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
    Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
    Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
    Mezei Z; Bereczki D; Csiba L; Csépány T
    Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis.
    Schröder A; Klotz P; Lee DH; Gold R; Linker RA
    Clin Neurol Neurosurg; 2011 Sep; 113(7):527-30. PubMed ID: 21429658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.